Yamaguchi Ryuji, Uchiyama Masanobu, Miyazaki Motoyasu, Hayashi Toshinobu, Oyabu Kohei, Nakano Takafumi, Matsuo Koichi
Department of Pharmacy, Kyushu Central Hospital, Fukuoka, Japan.
Department of Pharmacy, Fukuoka University Hospital, Fukuoka, Japan.
Cancer Diagn Progn. 2024 Nov 3;4(6):722-728. doi: 10.21873/cdp.10387. eCollection 2024 Nov-Dec.
BACKGROUND/AIM: Trastuzumab (TRA) is a key drug in human epidermal growth factor receptor type 2 (HER2)-positive breast cancer treatment. Infusion reactions (IR) with TRA are frequently observed in practice. Although the efficacy of premedication has been previously reported, it remains uncommon. The probability of severe IR due to TRA is low; however, when it does occur, it is associated with patient discomfort and expenditure of medical resources. This study aimed to analyze the factors associated with the occurrence of IR in patients with breast cancer who received TRA.
We retrospectively studied 204 patients who underwent TRA for breast cancer treatment between September 2008 and June 2023, identifying factors influencing the occurrence of IR at the time of TRA administration.
A total of 182 patients were included in this study, and the incidence of IR was 25.8% (47/182 patients). Multiple logistic regression analysis showed that pertuzumab (PER) use, high alkaline phosphatase (ALP), and low high-density lipoprotein (HDL) cholesterol levels were associated with IR.
IR should be considered when PER is combined with TRA. ALP and HDL cholesterol levels may be predictive markers of TRA-induced IR in patients with breast cancer.
背景/目的：曲妥珠单抗（TRA）是治疗人表皮生长因子受体2（HER2）阳性乳腺癌的关键药物。在实际应用中，TRA引起的输注反应（IR）较为常见。尽管先前已有关于预处理疗效的报道，但仍不常见。TRA导致严重IR的概率较低；然而，一旦发生，会给患者带来不适并消耗医疗资源。本研究旨在分析接受TRA治疗的乳腺癌患者发生IR的相关因素。
我们回顾性研究了2008年9月至2023年6月期间接受TRA治疗乳腺癌的204例患者，确定了TRA给药时影响IR发生的因素。
本研究共纳入182例患者，IR发生率为25.8%（47/182例患者）。多因素logistic回归分析显示，使用帕妥珠单抗（PER）、碱性磷酸酶（ALP）水平高和高密度脂蛋白（HDL）胆固醇水平低与IR相关。
当PER与TRA联合使用时应考虑IR。ALP和HDL胆固醇水平可能是乳腺癌患者TRA诱导IR的预测指标。
